Efficacy and Safety of Abrocitinib in an Elderly Chinese Population with Moderate-to-Severe Atopic Dermatitis: A Non-randomized Controlled Trial
DOI:
https://doi.org/10.2340/actadv.v105.44200Keywords:
atopic dermatitis in elderly, atopic dermatitis, elderly, older patients, abrocitinibAbstract
There is a paucity of data regarding the use of Janus kinase inhibitors in elderly patients with moderate-to-severe atopic dermatitis necessitating systemic therapy. This study aimed to evaluate the efficacy and safety of abrocitinib compared with dupilumab in atopic dermatitis patients aged 60 years or older. A single-centre, non-randomized controlled trial (ChiCTR2300077724) was conducted from December 2022 to March 2024, in which 58 patients were assigned to receive either abrocitinib (100 mg daily) or dupilumab (600 mg loading dose followed by 300 mg every 2 weeks). The primary endpoints were the proportion of patients achieving a ≥ 4-point reduction in the Peak Pruritus Numerical Rating Scale (PP-NRS) at Week 2 and the proportion achieving Eczema Area and Severity Index (EASI)-75 at Week 12; EASI-90 response at Week 24 was a key secondary endpoint. Results showed that a higher proportion of patients receiving abrocitinib achieved a PP-NRS4 response at Week 2 (52% vs 26%; p = 0.046). At Week 12, EASI-75 response rates were similar between the 2 groups (45% for abrocitinib vs 44% for dupilumab; p = 0.95). By Week 24, the EASI-90 response rate was 52% in the abrocitinib group compared with 41% in the dupilumab group (p = 0.4). Adverse events in the abrocitinib group included colon tumour (3%), nausea (6%), folliculitis (6%), and headache (16%), while the dupilumab group reported T-cell prolymphocytic leukaemia (3%) and conjunctivitis (7%). In conclusion, abrocitinib provided more rapid relief from pruritus and demonstrated superior long-term efficacy compared with dupilumab in the elderly population.
Downloads
References
Ständer S. Atopic Dermatitis. N Engl J Med 2021; 384: 1136–1143. DOI: https://doi.org/10.1056/NEJMra2023911
Napolitano M, Potestio L, Nocerino M, Patruno C. Considerations for managing elderly patients with atopic dermatitis. Expert Rev Clin Immunol 2024; 20: 501–511. DOI: https://doi.org/10.1080/1744666X.2024.2301967
Williamson S, Merritt J, De Benedetto A. Atopic dermatitis in the elderly: a review of clinical and pathophysiological hallmarks. Br J Dermatol 2020; 182: 47–54. DOI: https://doi.org/10.1111/bjd.17896
Yew YW, Thyssen JP, Silverberg JI. A systematic review and meta-analysis of the regional and age-related differences in atopic dermatitis clinical characteristics. J Am Acad Dermatol 2019; 80: 390–401. DOI: https://doi.org/10.1016/j.jaad.2018.09.035
Laughter MR, Maymone MBC, Mashayekhi S, Arents BWM, Karimkhani C, Langan SM, et al. The global burden of atopic dermatitis: lessons from the Global Burden of Disease Study 1990–2017. Br J Dermatol 2021; 184: 304–309. DOI: https://doi.org/10.1111/bjd.19580
Maurelli M, Chiricozzi A, Peris K, Gisondi P, Girolomoni G. Atopic dermatitis in the elderly population. Acta Derm Venereol 2023; 103. DOI: https://doi.org/10.2340/actadv.v103.13363
Bieber T, D’Erme AM, Akdis CA, Traidl-Hoffmann C, Lauener R, Schäppi G, et al. Clinical phenotypes and endophenotypes of atopic dermatitis: where are we, and where should we go? J Allergy Clin Immunol 2017; 139: S58–S64. DOI: https://doi.org/10.1016/j.jaci.2017.01.008
Wang S, Zhu R, Gu C, Zou Y, Yin H, Xu J, et al. Distinct clinical features and serum cytokine pattern of elderly atopic dermatitis in China. J Eur Acad Dermatol Venereol 2020; 34: 2346–2352. DOI: https://doi.org/10.1111/jdv.16346
Gu C, Yao X, Li W. Burden of disease: the current status of the diagnosis and management of atopic dermatitis in China. J Clin Med 2023; 12: 5370. DOI: https://doi.org/10.3390/jcm12165370
Wollenberg A, Kinberger M, Arents B, Aszodi N, Avila Valle G, Barbarot S, et al. European guideline (EuroGuiDerm) on atopic eczema: part I – systemic therapy. J Eur Acad Dermatol Venereol 2022; 36: 1409–1431. DOI: https://doi.org/10.1111/jdv.18345
Silverberg JI, Lynde CW, Abuabara K, Patruno C, de Benedetto A, Zhang H, et al. Efficacy and safety of dupilumab maintained in adults ≥ 60 years of age with moderate-to-severe atopic dermatitis: analysis of pooled data from four randomized clinical trials. Am J Clin Dermatol 2023; 24: 469–483. DOI: https://doi.org/10.1007/s40257-022-00754-4
Sreekantaswamy SA, Tully J, Edelman LS, Supiano MA, Butler D. The underrepresentation of older adults in clinical trials of Janus kinase inhibitors in the treatment of atopic dermatitis. J Am Acad Dermatol 2022; 87: 1174–1176. DOI: https://doi.org/10.1016/j.jaad.2022.02.051
Chan LN, Magyari A, Ye M, Al-Alusi NA, Langan SM, Margolis D, et al. The epidemiology of atopic dermatitis in older adults: a population-based study in the United Kingdom. PLoS One 2021; 16: e0258219. DOI: https://doi.org/10.1371/journal.pone.0258219
Drucker AM, Lam M, Prieto-Merino D, Malek R, Ellis AG, Yiu ZZN, et al. Systemic immunomodulatory treatments for atopic dermatitis: living systematic review and network meta-analysis update. JAMA Dermatol 2024; 160: 936–944. DOI: https://doi.org/10.1001/jamadermatol.2024.2192
Davis DMR, Drucker AM, Alikhan A, Bercovitch L, Cohen DE, Darr JM, et al. Guidelines of care for the management of atopic dermatitis in adults with phototherapy and systemic therapies. J Am Acad Dermatol 2024; 90: e43–e56. DOI: https://doi.org/10.1016/j.jaad.2023.08.102
Davis DMR, Drucker AM, Alikhan A, Bercovitch L, Cohen DE, Darr JM, et al. Executive summary: Guidelines of care for the management of atopic dermatitis in adults with phototherapy and systemic therapies. J Am Acad Dermatol 2024; 90: 342–345. DOI: https://doi.org/10.1016/j.jaad.2023.08.103
Müller S, Maintz L, Bieber T. Treatment of atopic dermatitis: recently approved drugs and advanced clinical development programs. Allergy 2024; 79: 1501–1515. DOI: https://doi.org/10.1111/all.16009
Wang SS, Pan XY, Li YN, Li W. [Efficacy and safety of new systemic therapies in moderate-to-severe atopic dermatitis in the elderly: meta-analysis]. Zhonghua Yi Xue Za Zhi 2023; 103: 2509–2515.
Hu YQ, Zhang JZ, Zhao Y. Efficacy and safety of dupilumab in Chinese elderly patients with atopic dermatitis: a real-world study. Dermatology 2024; 240: 589–596. DOI: https://doi.org/10.1159/000539355
Beck LA, Deleuran M, Bissonnette R, de Bruin-Weller M, Galus R, Nakahara T, et al. Dupilumab provides acceptable safety and sustained efficacy for up to 4 years in an open-label study of adults with moderate-to-severe atopic dermatitis. Am J Clin Dermatol 2022; 23: 393–408. DOI: https://doi.org/10.1007/s40257-022-00685-0
Ben Abdallah H, Vestergaard C. Atopic dermatitis, hypertension and cardiovascular disease. Br J Dermatol 2022; 186: 203–204. DOI: https://doi.org/10.1111/bjd.20802
Elmariah SB, Smith JS, Merola JF. JAK in the [black] box: a dermatology perspective on systemic JAK inhibitor safety. Am J Clin Dermatol 2022; 23: 427–431. DOI: https://doi.org/10.1007/s40257-022-00701-3
Ytterberg SR, Bhatt DL, Mikuls TR, Koch GG, Fleischmann R, Rivas JL, et al. Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis. N Engl J Med 2022; 386: 316–326. DOI: https://doi.org/10.1056/NEJMoa2109927
Piscazzi F, Gargiulo L, Ibba L, Valenti M, Facheris P, Costanzo A, et al. Upadacitinib for the treatment of atopic dermatitis in the elderly: an Italian case series of seven patients. J Dermatolog Treat 2023; 34: 2245510. DOI: https://doi.org/10.1080/09546634.2023.2245510
Bieber T, Simpson EL, Silverberg JI, Thaçi D, Paul C, Pink AE, et al. Abrocitinib versus placebo or dupilumab for atopic dermatitis. New Engl J Med 2021; 384: 1101–1112. DOI: https://doi.org/10.1056/NEJMoa2019380
Nezamololama N, Fieldhouse K, Metzger K, Gooderham M. Emerging systemic JAK inhibitors in the treatment of atopic dermatitis: a review of abrocitinib, baricitinib, and upadacitinib. Drugs Context 2020; 9: 2020-8-5. DOI: https://doi.org/10.7573/dic.2020-8-5
Silverberg JI, Simpson EL, Thyssen JP, Gooderham M, Chan G, Feeney C, et al. Efficacy and safety of abrocitinib in patients with moderate-to-severe atopic dermatitis. JAMA Dermatol 2020; 156: 863–873. DOI: https://doi.org/10.1001/jamadermatol.2020.1406
Simpson EL, Sinclair R, Forman S, Wollenberg A, Aschoff R, Cork M, et al. Efficacy and safety of abrocitinib in adults and adolescents with moderate-to-severe atopic dermatitis (JADE MONO-1): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial. Lancet 2020; 396: 255–266. DOI: https://doi.org/10.1016/S0140-6736(20)30732-7
Reich K, Thyssen JP, Blauvelt A, Eyerich K, Soong W, Rice ZP, et al. Efficacy and safety of abrocitinib versus dupilumab in adults with moderate-to-severe atopic dermatitis: a randomised, double-blind, multicentre phase 3 trial. Lancet 2022; 400: 273–282. DOI: https://doi.org/10.1016/S0140-6736(22)01199-0
Silverberg JI. Association between adult atopic dermatitis, cardiovascular disease, and increased heart attacks in three population-based studies. Allergy 2015; 70: 1300–1308. DOI: https://doi.org/10.1111/all.12685
Eichenfield LF, Flohr C, Sidbury R, Siegfried E, Szalai Z, Galus R, et al. Efficacy and safety of abrocitinib in combination with topical therapy in adolescents with moderate-to-severe atopic dermatitis: The JADE TEEN randomized clinical trial. JAMA Dermatol 2021; 157: 1165–1173. DOI: https://doi.org/10.1001/jamadermatol.2021.2830
Drucker AM, Lam M, Elsawi R, Prieto-Merino D, Malek R, Ellis AG, et al. Comparing binary efficacy outcomes for systemic immunomodulatory treatments for atopic dermatitis in a living systematic review and network meta-analysis. Br J Dermatol 2024; 190: 184–190. DOI: https://doi.org/10.1093/bjd/ljad393
Thyssen JP, Yosipovitch G, Paul C, Kwatra SG, Chu CY, DiBonaventura M, et al. Patient-reported outcomes from the JADE COMPARE randomized phase 3 study of abrocitinib in adults with moderate-to-severe atopic dermatitis. J Eur Acad Dermatol Venereol 2022; 36: 434–443. DOI: https://doi.org/10.1111/jdv.17813
Simpson EL, Silverberg JI, Thyssen JP, Viguier M, Thaçi D, de Bruin-Weller M, et al. Efficacy and safety of abrocitinib in patients with severe and/or difficult-to-treat atopic dermatitis: a post hoc analysis of the randomized phase 3 JADE COMPARE Trial. Am J Clin Dermatol 2023; 24: 609–621. DOI: https://doi.org/10.1007/s40257-023-00785-5
Ständer S, Kwatra SG, Silverberg JI, Simpson EL, Thyssen JP, Yosipovitch G, et al. Early itch response with abrocitinib is associated with later efficacy outcomes in patients with moderate-to-severe atopic dermatitis: subgroup analysis of the randomized phase III JADE COMPARE Trial. Am J Clin Dermatol 2023; 24: 97–107. DOI: https://doi.org/10.1007/s40257-022-00738-4
Wenkstetten-Holub A, Fangmeyer-Binder M, Fasching P. Prevalence of comorbidities in elderly cancer patients. Memo 2020; 14: 15–19. DOI: https://doi.org/10.1007/s12254-020-00657-2
Russell MD, Stovin C, Alveyn E, Adeyemi O, Chan CKD, Patel V, et al. JAK inhibitors and the risk of malignancy: a meta-analysis across disease indications. Ann Rheum Dis 2023; 82: 1059–1067. DOI: https://doi.org/10.1136/ard-2023-224049
Simpson EL, Silverberg JI, Nosbaum A, Winthrop K, Guttman-Yassky E, Hoffmeister KM, et al. Integrated safety update of abrocitinib in 3802 patients with moderate-to-severe atopic dermatitis: data from more than 5200 patient-years with up to 4 years of exposure. Am J Clin Dermatol 2024; 25: 639–654. DOI: https://doi.org/10.1007/s40257-024-00869-w
Beck LA, Bissonnette R, Deleuran M, Nakahara T, Galus R, Coleman A, et al. Dupilumab in adults with moderate to severe atopic dermatitis: a 5-year open-label extension study. JAMA Dermatol 2024; 160: 805–812. DOI: https://doi.org/10.1001/jamadermatol.2024.1536
Hasan I, Parsons L, Duran S, Zinn Z. Dupilumab therapy for atopic dermatitis is associated with increased risk of cutaneous T cell lymphoma: a retrospective cohort study. J Am Acad Dermatol 2024; 91: 255–258. DOI: https://doi.org/10.1016/j.jaad.2024.03.039
Published
How to Cite
License
Copyright (c) 2025 Quanhong Zhang, Yue Zhu, Luoyao Yang, Yueping Zeng, Hongmei Zhang, Lang Yu, Gang Hu, Lei Hu, Liuqing Chen, Jinbo Chen
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All digitalized ActaDV contents is available freely online. The Society for Publication of Acta Dermato-Venereologica owns the copyright for all material published until volume 88 (2008) and as from volume 89 (2009) the journal has been published fully Open Access, meaning the authors retain copyright to their work.
Unless otherwise specified, all Open Access articles are published under CC-BY-NC licences, allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material for non-commercial purposes, provided proper attribution to the original work.
